EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.
Nicholas P GiustiniColin C PritchardNikhil V KamatManoj P MenonPublished in: JCO precision oncology (2024)
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.